



## 發明名稱

發明人：張正琪 副教授  
單位：國立臺灣大學 口腔生物科學研究所  
簡歷：(可列出相關連結，例如系所、研究室網頁)  
www.ntuccc.com

請放任一代表照片  
(不可揭露技術內容)

### 市場及需求：

口腔癌為目前世界上癌症死亡肇因前 10 名，其發生率亦每年上升，5 年存活率只有 55%。且沒有專一有效相關標靶治療藥物。

### 技術摘要(含成果)：

結締組織生長因子，經台大牙科研究團隊證實為口腔癌新發現之抑癌基因。本發明研究結果顯示：結締組織生長因子蛋白之早期偵測明顯下降-可能指示病人預後不佳，建議積極使用後藥物或佐以其他療法，而蛋白本身則有治療口腔癌癌症淋巴轉移之功效。

### 優勢：

口腔癌目前並無臨床上可供使用之標靶藥物，故無現有技術可資比較。技術創新度高，臨床發展可期待。

### 競爭產品：

目前臨床上並無專一抑制口腔癌之相關藥物或製劑

### 專利現況：

(1) 本技術已有相關專利：

美國專利證號：  
US2005/0147986  
US2007/0172876  
US2012/0165253  
US8,871,721 B2

(2) 本研究團隊具有數十年研究經驗

### 聯絡方式(請不用填)：

臺大產學合作總中心

Tel: 02-3366-9945, E-mail: ntuciac@ntu.edu.tw

本資料僅供國立臺灣大學專利/技術申請使用，嚴禁使用全部或部分內容於其他用途。若有疑問請與我們聯繫，我們將盡力協助您。



# Title of Invention

(Below is limited to 1-page only; be careful not to disclose vital technology content. Please delete these words when the document is finished)

**PI :** Associate Professor Cheng-Chi Chang  
Graduate Institute of Oral Biology, College of Medicine,  
National Taiwan U.

**Experience:**  
www.ntuccc.com

An interesting **photo** related to  
your technology  
(be careful not to disclose key  
technology)

**Market Needs:**  
Oral squamous cell carcinoma (OSCC) is one of the top 10 most common causes of death, and the rate of occurrence is increasing every year. More than 50% of patients die from this disease or complications within 5 years.

**Our Technology:**  
Connective tissue growth factor is a newly defined tumor suppressor gene in oral cancer. We claimed that early decreased this small protein could indicate poor prognosis in oral cancer patients, and we suggested that the population expressed low CTGF in lesion part may consider to combine treatment with advanced radiotherapy or chemotherapy after operation. CTGF also been proved to inhibit lymph node metastasis.

**Strength:**  
There are no target therapy drug to be chosen in oral cancer clinically. Hence, no exciting technologies could be compared with the applicant. The perspective of clinical development is well-expected.

**Competing Products:**  
There are no target therapy drug to be chosen in oral cancer clinically.

**Intellectual Properties:**  
US2005/0147986  
US2007/0172876  
US2012/0165253  
US8,871,721 B2

**Contact (do not need to fill out):**  
Center for Industry-Academia Cooperation, NTU  
Tel: 02-3366-9945, E-mail: ntuciac@ntu.edu.tw

This information herein is intended for potential license of NTU technology only. Other usage of all or portion of this information in whatever form or means is strictly prohibited. Kindly contact us and we will help to achieve your goal the best we can.